Program
ublituximab
Also written as “Ublituximab”, “Cosibelimab + Ublituximab + Bendamustine combination” and “TGR-1202 + Ublituximab”.
Its studies are mostly in Multiple Sclerosis · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Schizophrenia · Myasthenia Gravis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TG Therapeutics | 227 open or running | phase 3since Nov 20, 2014 | Jul 17, 2012 | Jan 21, 2027phase 3 · NCT05877963 |
| Laboratoire français de Fractionnement et de Biotechnologies | 10 open or running | phase 1since Mar 31, 2010 | Mar 31, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Mar 31, 2010.
- Nov 18, 2015Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT02612311 · 603 enrolled · United States, Israel, Italy and more
- Jan 13, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT02656303 · 116 enrolled · United States, Italy, Poland and more
- Apr 10, 2016Phase 2 study in Multiple SclerosisTG Therapeutics · NCT02738775 · 49 enrolled · United States
- Jun 28, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT03207256 · 51 enrolled · United States
- Sep 7, 20172 phase 3 studies in Relapsing Multiple Sclerosis (RMS)TG Therapeutics · NCT03277261, NCT03277248
- Dec 18, 2017Phase 2 study in Multiple Sclerosis, Relapsing-RemittingTG Therapeutics · NCT03381170 · 48 enrolled · United States
- Dec 11, 2018Phase 1 study in Lymphoma, B-CellTG Therapeutics · NCT03778073 · 18 enrolled · United States
- Jan 9, 2019Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT03801525 · 277 enrolled · United States
- Jan 31, 2019Phase 2 study in Lymphoma, FollicularTG Therapeutics · NCT03828448 · 34 enrolled · United States
- Oct 16, 2019Phase 3 study in Relapsing Multiple Sclerosis (RMS)TG Therapeutics · NCT04130997 · 1,100 enrolled · United States, Belarus, Croatia and more
- May 18, 2023Phase 3 study in Relapsing Multiple SclerosisTG Therapeutics · NCT05877963 · 800 planned · United States, Poland
- Oct 1, 20252 phase 3 studies in Relapsing Multiple SclerosisTG Therapeutics · NCT07211633, NCT07220252
- Mar 9, 2026Phase 2 study in Multiple SclerosisTG Therapeutics · NCT07503873 · 350 planned · Bosnia and Herzegovina, Georgia, North Macedonia and more
- Jun 10, 20262 phase 2 studiesTG Therapeutics · NCT07673744, NCT07680946
Ahead
- Jan 21, 2027Primary completion: phase 3 study in Relapsing Multiple SclerosisTG Therapeutics · NCT05877963
- Jul 31, 2027Primary completion: phase 2 study in Multiple SclerosisTG Therapeutics · NCT07503873
- Jul 1, 2028Primary completion: phase 2 study in Myasthenia GravisTG Therapeutics · NCT07673744
- Dec 12, 2028Primary completion: phase 2 study in SchizophreniaTG Therapeutics · NCT07680946
TargetBeta
“A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 ”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07680946Schizophrenia · United States | 2 | Recruiting | TG Therapeutics | Dec 12, 2028 | 60 |
| NCT07673744Myasthenia Gravis · United States | 2 | Recruiting | TG Therapeutics | Jul 1, 2028 | 120 |
| NCT07503873Multiple Sclerosis · Bosnia and Herzegovina, Georgia, North Macedonia and more | 2 | Recruiting | TG Therapeutics | Jul 31, 2027 | 350 |
| NCT07220252Relapsing Multiple Sclerosis · United States, Poland, Slovakia | 3 | Recruiting | TG Therapeutics | Jan 1, 2030 | 240 |
| NCT07211633Relapsing Multiple Sclerosis · Bosnia and Herzegovina, Bulgaria, Croatia and more | 3 | Active, not recruiting | TG Therapeutics | Oct 31, 2026 | 360 |
| NCT05877963Relapsing Multiple Sclerosis · United States, Poland | 3 | Recruiting | TG Therapeutics | Jan 21, 2027 | 800 |
| NCT04130997Relapsing Multiple Sclerosis (RMS) · United States, Belarus, Croatia and more | 3 | Active, not recruiting | TG Therapeutics | May 31, 2032 | 1,100 |
| NCT03828448Lymphoma, Follicular · United States | 2 | Terminated | TG Therapeutics | May 16, 2022 | 34 |
| NCT03801525Leukemia, Lymphocytic, Chronic, B-Cell · United States | 3 | Terminated | TG Therapeutics | Dec 20, 2022 | 277 |
| NCT03778073Lymphoma, B-Cell · United States | 1 | Terminated | TG Therapeutics | May 3, 2022 | 18 |
| NCT03381170Multiple Sclerosis, Relapsing-Remitting · United States | 2 | Completed | TG Therapeutics | Nov 11, 2022 | 48 |
| NCT03277261Relapsing Multiple Sclerosis (RMS) · United States | 3 | Completed | TG Therapeutics | Jul 23, 2020 | 549 |
| NCT03277248Relapsing Multiple Sclerosis (RMS) · United States | 3 | Completed | TG Therapeutics | Aug 4, 2020 | 545 |
| NCT03207256Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Terminated | TG Therapeutics | May 25, 2022 | 51 |
| NCT02738775Multiple Sclerosis · United States | 2 | Completed | TG Therapeutics | Sep 27, 2017 | 49 |
| NCT02656303Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, Poland and more | 2 | Terminated | TG Therapeutics | May 26, 2022 | 116 |
| NCT02612311Leukemia, Lymphocytic, Chronic, B-Cell · United States, Israel, Italy and more | 3 | Terminated | TG Therapeutics | Feb 22, 2023 | 603 |
| NCT02301156Leukemia, Lymphocytic, Chronic, B-Cell · United States, Israel | 3 | Completed | TG Therapeutics | Apr 1, 2020 | 126 |
| NCT02013128Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | TG Therapeutics | Dec 2015 | 66 |
| NCT02006485Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Completed | TG Therapeutics | Oct 2019 | 160 |
| NCT01744912Lymphoma, Non-Hodgkin · United States | 1 | Terminated | TG Therapeutics | Feb 7, 2014 | 10 |
| NCT01647971Lymphoma, Non-Hodgkin · United States | 2 | Completed | TG Therapeutics | May 2015 | 39 |
| NCT01098188Leukemia, Lymphocytic, Chronic, B-Cell · France | 1 | Completed | Laboratoire français de Fractionnement et de Biotechnologies | Aug 2011 | 33 |
How it is read
Names in the registry
- “Ublituximab”, 21 entries
- “Cosibelimab + Ublituximab + Bendamustine combination”, 2 entries
- “TGR-1202 + Ublituximab”, 1 entry
- “Ublituximab + TGR-1202”, 1 entry
- “Ublituximab + TGR-1202 + ibrutinib”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 8 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 8 studies
- Lymphoma, B-Cell, 2 studies
- Schizophrenia, 1 study
- Myasthenia Gravis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.